Determinants of C1q binding in the single antigen bead assay

Transplantation

Volumn 98, Issue 4, 2014, Pages 387-393

  Schaub, Stefan ^a   Hönger, Gideon ^a   Koller, Michael T ^a   Liwski, Robert ^b   Amico, Patrizia ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

C1q binding; HLA antibodies; Renal transplantation; Risk assessment; Single antigen bead

Indexed keywords

COMPLEMENT COMPONENT C1Q; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; ALLOANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN G;

ADULT; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE ANTIGEN BEAD ASSAY; BLOOD; CLASSIFICATION; IMMUNOLOGY; MIDDLE AGED; STATISTICAL MODEL;

ADULT; COMPLEMENT C1Q; FEMALE; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; ISOANTIBODIES; LOGISTIC MODELS; MALE; MIDDLE AGED;

EID: 84908012918     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000203     Document Type: Article

References (24)

1. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012; 8: 670.
2. Baldwin WM III, Pruitt SK, Brauer RB, et al. Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation 1995; 59: 797.
3. Kushihata F, Watanabe J, Mulder A, et al. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential. Transplantation 2004; 78: 995.
4. Bartel G, Wahrmann M, Exner M, et al. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 2007; 83: 727.
5. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43.
6. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849.
7. Otten HG, Verhaar MC, Borst HP, et al. Pretransplant donor-specific HLA class-I and-II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12: 1618.
8. Crespo M, Torio A, Mas V, et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl Immunol 2013; 29: 28.
9. Lachmann N, Todorova K, Schulze H, et al. Systematic comparison of four cell-and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 2013; 95: 694.
10. Liwski R, Lee S, Sperry R, et al. The antiYhuman globulin enhanced C1qScreen(Tm) assay improves the detection of complement binding donor specific HLA-antibodies (abstract 60-OR). Hum Immunol 2013; 74: 1.
11. Liwski R, Lee S, Sperry R, et al. Anti-human globulin enhanced C1qScreen(Tm) assay positivity correlates with the CDC-AHG cross-match results (abstract 61-OR). Hum Immunol 2013; 74: 1.
12. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684.
13. Kimball PM, Baker MA, Wagner MB, et al. Surveillance of alloanti-bodies after transplantation identifies the risk of chronic rejection. Kidney Int 2011; 79: 1131.
14. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215.
15. Yabu JM, Higgins JP, Chen G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopa-thy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342.
16. Arnold ML. Donor specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to non-complement fixing IgG2/IgG4 anti HLA alloantibodies. Transpl Int 2013; Oct 13. DOI: 10.1111/tri.12206 [Epub ahead of print].
17. Lowe D, Higgins R, Zehnder D, et al. Significant IgG subclass heterogeneity in HLA-specific antibodies: implications for pathogenicity, prognosis, and the rejection response. Hum Immunol 2013; 74: 666.
18. Honger G, Hopfer H, Arnold ML, et al. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 2011; 92: 41.
19. Murata K, Fox-Talbot K, Qian Z, et al. Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Transplant 2007; 7: 2605.
20. Schnaidt M, Weinstock C, Jurisic M, et al. HLA antibody specification using single-antigen beadsVa technical solution for the prozone effect. Transplantation 2011; 92: 510.
21. Zhang X, Reed EF, Cecka M, et al. Positivity in the C1q Assay depends on the HLA antibody strength (abstract 62-OR). Hum Immunol 2013; 74: 1.
22. Duquesnoy RJ, Marrari M, Jelenik L, et al. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays. Hum Immunol 2013; 74: 1271.
23. Fuller TC, Fuller AA, Golden M, et al. HLA alloantibodies and the mechanism of the antiglobulin-augmented lymphocytotoxicity procedure. Hum Immunol 1997; 56: 94.
24. Bachler K, Amico P, Honger G, et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010; 10: 1254.